Immune cell therapy shows promise for tough skin cancers
NCT ID NCT07288073
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a treatment using a patient's own immune cells (called tumor-infiltrating lymphocytes or TILs) combined with chemotherapy and interleukin-2 for people with advanced cutaneous squamous cell carcinoma or Merkel cell carcinoma who have already tried immunotherapy. The goal is to see if this approach is safe and can shrink tumors. About 14 adults will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your genes predict your melanoma risk?
- A UV photo and a cheek swab may be the keys to stopping sunburn before it starts
- Could a lighter immunotherapy schedule keep advanced cancers in check?
- Night shift workers' skin may struggle to fix sun damage, study suggests
- Immunotherapy before surgery may cut skin cancer recurrence
- Blood clot marker may predict immunotherapy success in advanced skin cancer